SCHEMBL5145754

SCHEMBL5145754

O=C(CC(=O)Nc1cccc(C(=O)O)c1)Nc1cccc(C(=O)O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.62
MEN1 O00255 3/20 0.62
NPC1 O15118 7/20 0.61
RAB9A P51151 7/20 0.61
SMN1; SMN2 Q16637 6/20 0.61
ALDH1A1 P00352 1/20 0.61
HTT P42858 1/20 0.61
HIF1A Q16665 1/20 0.60
EPAS1 Q99814 1/20 0.60
L3MBTL1 Q9Y468 2/20 0.58
MITF O75030 2/20 0.58
KDM4E B2RXH2 1/20 0.58
MAPT P10636 1/20 0.58
HSD17B10 Q99714 1/20 0.58
NFKB1 P19838 1/20 0.58
NFKB2 Q00653 1/20 0.58
RELA Q04206 1/20 0.58
PAX8 Q06710 1/20 0.58
KLF5 Q13887 1/20 0.58
HPSE Q9Y251 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28172169 0.93 NPC1 (0.58) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2562988 0.90 SMN1; SMN2 (0.59) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL9912441 0.89 NPC1 (0.58) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL8914692 0.87 SMN1; SMN2 (0.61) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL5197892 0.87 NPC1 (0.57) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL11508333 0.87 SMN1; SMN2 (0.57) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2113107 0.87 ALDH1A1 (0.60) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL31022670 0.87 ALDH1A1 (0.60) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL31444807 0.87 NPC1 (0.57) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL10964661 0.87 L3MBTL1 (0.77) KMT2AMEN1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2007-02-22 US disclosed
WO-2005037196-A2 SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CASP14, CASP2, CASP3 KMT2A 1674/4885MEN1 2893/4885NPC1 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.